Our work is interdisciplinary. We combine our competences in cytomorphology, immunophenotyping, molecular genetics, chromosome analysis and FISH and thereby provide the ideal basis for an optimized, individualized, and highly reliable diagnosis. The responsibility for our patients is the center of our activities.
Immunophenotyping is key to the diagnostics of hematologic neoplasia. It is used to complete diagnosis, classify diseases, assess prognoses and to quantify malignant cells over the course of treatment. Diagnostic application of the method is based on the characterization of antigen expression patterns among malignant cells and their discrimination from healthy cells.
We have contributed to a broad variety of collaborations on scientific issues for 20 years through our international networks with other diagnostic laboratories and research groups around the world.
We regularly participate in round robin tests by the following organizations as part of our quality assurance strategy:
- INSTAND e.V.
- Round robin test for quality assurance in FISH diagnostics for tumor cytogenics (QUITZ) (BVDH); round robin test for quality assurance in tumor cytogenics – chromosome banding analysis (BVDH); Cytogenic European Quality Assessment (CEQA)
- Round robin tests for quality assurance in molecular diagnostics (UK NEQAS) Certificate
- The international conversion factor for BCR-ABL quantification was determined by the EUTOS (European Treatment and Outcome Study) Certificate
- European Research Initiative on CLL (ERIC), IG Certified Center Certificate
MLL has been accredited according to DIN EN ISO 15189 and DIN EN ISO 17025 since 2009. The standards incorporate the contents of DIN EN ISO 9000 and DIN EN ISO 9001. Click here for the accreditation certificate according to DIN EN ISO 15189 and here for the accreditation certificate according to DIN EN ISO 17025.